Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $86.71.
Several equities analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $115.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 12th. The Goldman Sachs Group raised Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and increased their price target for the stock from $56.00 to $67.00 in a research report on Thursday, June 6th. Bank of America cut their price target on Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating on the stock in a research report on Friday, May 31st. Wedbush increased their price target on Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the stock a “neutral” rating in a research report on Friday, May 31st. Finally, TD Cowen increased their price target on Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th.
View Our Latest Stock Report on RARE
Insider Activity
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Franklin Resources Inc. lifted its stake in Ultragenyx Pharmaceutical by 13.3% in the 4th quarter. Franklin Resources Inc. now owns 214,738 shares of the biopharmaceutical company’s stock worth $10,269,000 after purchasing an additional 25,144 shares in the last quarter. Rafferty Asset Management LLC lifted its stake in Ultragenyx Pharmaceutical by 21.2% in the 4th quarter. Rafferty Asset Management LLC now owns 221,910 shares of the biopharmaceutical company’s stock worth $10,612,000 after purchasing an additional 38,859 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Ultragenyx Pharmaceutical by 5.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 396,725 shares of the biopharmaceutical company’s stock worth $14,143,000 after purchasing an additional 19,487 shares in the last quarter. New York State Common Retirement Fund lifted its stake in Ultragenyx Pharmaceutical by 37.0% in the 4th quarter. New York State Common Retirement Fund now owns 72,866 shares of the biopharmaceutical company’s stock worth $3,484,000 after purchasing an additional 19,673 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its stake in Ultragenyx Pharmaceutical by 42.5% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 57,000 shares of the biopharmaceutical company’s stock worth $2,745,000 after purchasing an additional 17,000 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.
Ultragenyx Pharmaceutical Price Performance
NASDAQ RARE opened at $41.10 on Friday. The stock’s fifty day moving average price is $41.29 and its 200 day moving average price is $45.06. Ultragenyx Pharmaceutical has a 1 year low of $31.52 and a 1 year high of $54.56. The company has a market cap of $3.42 billion, a price-to-earnings ratio of -5.12 and a beta of 0.60.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 425.63%. The firm had revenue of $108.83 million during the quarter, compared to analyst estimates of $116.03 million. During the same period in the previous year, the company earned ($2.33) earnings per share. Ultragenyx Pharmaceutical’s revenue was up 8.3% on a year-over-year basis. Research analysts expect that Ultragenyx Pharmaceutical will post -6.43 earnings per share for the current year.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Recommended Stories
- Five stocks we like better than Ultragenyx Pharmaceutical
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 3 Small Caps With Big Return Potential
- MarketBeat Week in Review – 6/24 – 6/28
- How to Use the MarketBeat Stock Screener
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.